Search results
The Evolution Of Antibody-Drug Manufacturing
BioresearchOnline· 5 days agoWere antibody-drug conjugates (ADCs) the magic bullets everyone was looking for that could, among other things, cure cancer? The evolution of ADCs is a stunning example of ...
Kymera reports promising Phase 1 results for KT-333 cancer drug By Investing.com
Investing.com· 1 day agoKymera Therapeutics Inc. (NASDAQ: KYMR), a biopharmaceutical firm focused on advancing protein...
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
BioPharma Dive via Yahoo Finance· 1 day agoThe Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P....
Pediatric brain tumors rely on different metabolic | Newswise
Newswise· 2 days agoResearchers at the University of Michigan Health Rogel Cancer Center are one step closer to understanding how pediatric DIPG tumors work.
Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias...
WWTI Watertown· 2 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
Deadliest Catch star Nick Mavar dies aged 59 after ‘medical emergency’
The Independent US via AOL· 20 hours agoMavar sought $1m in damages. The boat’s owners later filed a lawsuit against the production company...
New cancer treatment increases efficacy by injecting chemo directly into tumor cells
BGR· 6 days agoChemotherapy has proven to be a fairly successful treatment for cancer. The Food and Drug...
Immunotherapy Before Surgery Leads to Better Outcomes for People with Colon Cancer
Healthline via AOL· 7 days agoBut we can’t draw that conclusion from this study yet. It’s going a little too far to say,” she...
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
Zacks· 1 day agoSL-172154 is an investigational agonist redirected checkpoint fusion protein, designed to simultaneously inhibit the CD47/SIRPα checkpoint interaction and activate the CD40 costimulatory receptor ...
New EHA data reveal how badly Gilead's $4.9B bet on CD47 imploded
FierceBiotech· 21 hours agoGilead Sciences' abandoned anti-CD47 drug magrolimab was not just ineffective, but could potentially...